Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Thoracic 1Head & Neck 1

Conditions

Melanoma 2Squamous Cell Carcinoma of Head and Neck 1Melanoma, Cutaneous Malignant 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 131Carboplatin 106Paclitaxel 66Cisplatin 61Gemcitabine 57Pemetrexed 56Bevacizumab 50Docetaxel 47Fluorouracil 40Oxaliplatin 38Dexamethasone 34130-nm albumin-bound paclitaxel 34Leucovorin 33atezolizumab 32Cetuximab 32durvalumab 30Nivolumab 28Rituximab 26Cyclophosphamide 26Capecitabine 26Prednisone 25Fulvestrant 24enzalutamide 23Lenalidomide 22venetoclax 21Letrozole 20Irinotecan 20Doxorubicin 17ribociclib 16pomalidomide 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Opdualag × 30 days × Clear all
NCT05625399 2026-06-03

RELATIVITY-127

Bristol-Myers Squibb

Phase 3 Active not recruiting
579 enrolled
Dermatologic

Melanoma

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting
360 enrolled
Dermatologic

Melanoma, Cutaneous Malignant

NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Iovance Biotherapeutics, Inc.

Phase 2 Terminated
225 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡